ERBB2 and breast carcinoma: To investigate the in vivo efficacy of lumretuzumab plus pertuzumab, we established an ER+/HER2-low/HER3+ human breast cancer mouse xenograft model using human breast cancer tissue derived from a woman with invasive lobular carcinoma.